Literature DB >> 26899887

Autoimmune encephalitis.

M P Newman1, S Blum2,3, R C W Wong1,4, J G Scott5,6, K Prain4, R J Wilson4, D Gillis1,4.   

Abstract

Over the past decade, the clinical spectrum of autoimmune encephalitis has expanded with the emergence of several new clinicopathological entities. In particular, autoimmune encephalitis has recently been described in association with antibodies to surface receptors and ion channels on neurological tissues. Greater clinician awareness has resulted in autoimmune encephalitis being increasingly recognised in patients with unexplained neurological and psychiatric symptoms and signs. The clinical spectrum of presentations, as well as our understanding of disease mechanisms and treatment regimens, is rapidly developing. An understanding of these conditions is important to all subspecialties of Internal Medicine, including neurology and clinical immunology, psychiatry, intensive care and rehabilitation medicine. This review provides a contemporary overview of the aetiology, investigations and treatment of the most recently described autoimmune encephalitides.
© 2016 Royal Australasian College of Physicians.

Entities:  

Keywords:  anti-NMDAR; anti-VGKC; autoimmune encephalitis; limbic encephalitis; neuronal surface antigen antibody

Mesh:

Substances:

Year:  2016        PMID: 26899887     DOI: 10.1111/imj.12974

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  19 in total

Review 1.  [Cell depletion and myoablation for neuroimmunological diseases].

Authors:  M Diebold; L Kappos; T Derfuss
Journal:  Nervenarzt       Date:  2016-08       Impact factor: 1.214

Review 2.  Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults.

Authors:  Martin Holtkamp
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

3.  When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study.

Authors:  Bondish Kambadja; Houot Marion; Louis Cousyn; Nicolas Mezouar; Vincent Navarro; Bastien Herlin; Dupont Sophie
Journal:  J Neurol       Date:  2021-11-23       Impact factor: 4.849

4.  Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications.

Authors:  Kornelius Fuchs; Silke Rummler; Wolfgang Ries; Matthias Helmschrott; Jochen Selbach; Friedlinde Ernst; Christian Morath; Adelheid Gauly; Saynab Atiye; Manuela Stauss-Grabo; Mareike Giefer
Journal:  Ther Apher Dial       Date:  2021-05-06       Impact factor: 2.195

Review 5.  Innate and adaptive immunity in human epilepsies.

Authors:  Jan Bauer; Albert J Becker; Wassim Elyaman; Jukka Peltola; Stephan Rüegg; Maarten J Titulaer; James A Varley; Ettore Beghi
Journal:  Epilepsia       Date:  2017-07       Impact factor: 5.864

6.  The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis.

Authors:  James G Scott; David Gillis; Alex E Ryan; Hethal Hargovan; Nagaraj Gundarpi; Gemma McKeon; Sean Hatherill; Martin P Newman; Peter Parry; Kerri Prain; Sue Patterson; Richard C W Wong; Robert J Wilson; Stefan Blum
Journal:  BJPsych Open       Date:  2018-03-16

Review 7.  Systematic Review: Syndromes, Early Diagnosis, and Treatment in Autoimmune Encephalitis.

Authors:  Christina Hermetter; Franz Fazekas; Sonja Hochmeister
Journal:  Front Neurol       Date:  2018-09-05       Impact factor: 4.003

8.  Evaluation of Clinical and Paraclinical Findings for the Differential Diagnosis of Autoimmune and Infectious Encephalitis.

Authors:  Judith N Wagner; Ognian Kalev; Michael Sonnberger; Ingomar Krehan; Tim J von Oertzen
Journal:  Front Neurol       Date:  2018-06-08       Impact factor: 4.003

9.  Delirious Mania Associated with Autoimmune Gastrothyroidal Syndrome of a Mid-Life Female: The Role of Hashimoto Encephalopathy and a 3-Year Follow-Up including Serum Autoantibody Levels.

Authors:  Udo Bonnet; Claudia Selle; Ralf Kuhlmann
Journal:  Case Rep Psychiatry       Date:  2016-09-01

Review 10.  Autoimmune phenotypes in schizophrenia reveal novel treatment targets.

Authors:  Emily G Severance; Faith B Dickerson; Robert H Yolken
Journal:  Pharmacol Ther       Date:  2018-05-06       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.